This proved to be a formative year in the fight against Parkinson’s. Check out ASAP’s 2020 efforts and progress in better understanding the underlying causes of PD.

This program funds academic medical centers worldwide to train new movement disorder clinician-researchers over a two-year period. Please note the deadline for this opportunity has now passed.

The Lancet highlights the work we do with our AMP-PD partners in enabling meaningful progress in the development of new therapies to treat Parkinson’s disease.

Philanthropy News Digest featured ASAP in this article detailing what our grantees hope to accomplish with their research.

This article from News Medical Life Sciences highlights new studies describing unprecedented details of a protein linked to genetically inherited Parkinson's disease.

Based at UCL, the PhD will involve collaboration with world leaders in PD genetics across the GP2 network. The application deadline is August 31, 2020.

Global Parkinson's Genetics Program (GP2) will support the ongoing search for new genetic determinants of Parkinson's disease in diverse populations.

ASAP is committed to making full and immediate open access a reality. The future is science without publication paywalls.

Point of view from ASAP scientific director, Randy Schekman, PhD and managing director, Ekemini A. U. Riley, PhD.